Top MarketRank™ StocksTop MarketRank™Most-Downgraded StocksMost-DowngradedNASDAQ:DXCM DexCom (DXCM) Stock Price, News & Analysis $70.79 +2.18 (+3.18%) (As of 10:43 AM ET) Add Compare Share Share Today's Range$68.74â–Ľ$71.2750-Day Range$64.00â–Ľ$116.0652-Week Range$62.34â–Ľ$142.00Volume712,758 shsAverage Volume3.78 million shsMarket Capitalization$28.37 billionP/E Ratio45.67Dividend YieldN/APrice Target$112.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get DexCom alerts: Email Address DexCom MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.72 Rating ScoreUpside/Downside63.6% Upside$112.25 Price TargetShort InterestHealthy1.89% of Shares Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment0.17Based on 46 Articles This WeekInsider TradingSelling Shares$369,052 Sold Last QuarterProj. Earnings Growth18.93%From $1.69 to $2.01 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.94 out of 5 starsMedical Sector12th out of 909 stocksSurgical & Medical Instruments Industry3rd out of 97 stocks 4.4 Analyst's Opinion Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.72, and is based on 11 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageDexCom has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DexCom's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.89% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently increased by 7.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDexCom has received a 75.05% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Continuous glucose monitoring systems" and "Blood glucose monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for DexCom is -0.76. Previous Next 1.8 News and Social Media Coverage News SentimentDexCom has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 46 news articles for DexCom this week, compared to 16 articles on an average week.Search InterestOnly 40 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $369,052.00 in company stock.Percentage Held by InsidersOnly 0.30% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DexCom's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for DexCom are expected to grow by 18.93% in the coming year, from $1.69 to $2.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 44.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 118.34.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 44.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 79.88.Price to Earnings Growth RatioDexCom has a PEG Ratio of 2.12. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 12.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DexCom's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> About DexCom Stock (NASDAQ:DXCM)DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Read More DXCM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXCM Stock News HeadlinesAugust 13, 2024 | marketbeat.comTop 3 Stocks to Watch: Options Traders Bet on Big Gains (DXCM)Three stocks have stood out for call option traders to bet on in the coming months as a view for a recovery rally after an S&P 500 sell-off last weekSeptember 9 at 5:45 AM | prnewswire.comDexCom, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before October 21, 2024 to Discuss Your Rights - DXCMSeptember 9, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…September 8 at 4:49 AM | markets.businessinsider.comROSEN, LEADING TRIAL ATTORNEYS, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DXCMSeptember 7 at 7:16 AM | globenewswire.comDXCM DEADLINE REMINDER: DexCom, Inc. Investors who Lost Money are Reminded to Contact BFA Law before Upcoming Securities Litigation Deadline (Nasdaq:DXCM)September 6 at 6:00 PM | prnewswire.comDXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud LawsuitSeptember 6 at 4:29 PM | prnewswire.comDXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud LawsuitSeptember 6 at 3:02 PM | markets.businessinsider.comDexCom (DXCM) Faces Investor Backlash After Disappointing Earnings Report - Hagens BermanSeptember 9, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…September 6 at 5:45 AM | prnewswire.comInvestors who lost money on DexCom, Inc.(DXCM) should contact Levi & Korsinsky about pending Class Action - DXCMSeptember 5, 2024 | markets.businessinsider.comTOP RANKED ROSEN LAW FIRM Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DXCMSeptember 5, 2024 | globenewswire.comDXCM Lawsuit Reminder: Robbins LLP Encourages DexCom Inc. Stockholders to Seek Counsel for Class Action LawsuitSeptember 5, 2024 | globenewswire.comROSEN, NATIONAL TRIAL LAWYERS, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCMSeptember 5, 2024 | globenewswire.comDXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!September 5, 2024 | globenewswire.comDexCom (DXCM) Faces Investor and Analyst Backlash After Revealing Disappointing Growth - Hagens BermanSeptember 5, 2024 | globenewswire.comContact Levi & Korsinsky by October 21, 2024 Deadline to Join Class Action Against DexCom, Inc. (DXCM)September 5, 2024 | msn.comHere’s Why DexCom (DXCM) Fell in Q2September 5, 2024 | prnewswire.comDexCom, Inc. (DXCM) Investors: October 21, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLPSee More Headlines Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/25/2024Today9/08/2024Next Earnings (Estimated)10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:DXCM CUSIP25213110 CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees9,600Year Founded1999Price Target and Rating Average Stock Price Target$112.25 High Stock Price Target$161.00 Low Stock Price Target$75.00 Potential Upside/Downside+63.6%Consensus RatingModerate Buy Rating Score (0-4)2.72 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$1.55 Trailing P/E Ratio44.26 Forward P/E Ratio40.60 P/E Growth2.15Net Income$541.50 million Net Margins16.95% Pretax Margin20.51% Return on Equity31.41% Return on Assets10.84% Debt Debt-to-Equity Ratio1.00 Current Ratio2.82 Quick Ratio2.48 Sales & Book Value Annual Sales$3.93 billion Price / Sales6.93 Cash Flow$2.05 per share Price / Cash Flow33.51 Book Value$6.07 per share Price / Book11.30Miscellaneous Outstanding Shares397,684,000Free Float396,491,000Market Cap$27.29 billion OptionableOptionable Beta1.18 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Kevin Ronald Sayer (Age 66)Executive Chairman, CEO & President Comp: $3.23MMr. Jereme M. Sylvain (Age 44)Executive VP, CFO & Chief Accounting Officer Comp: $1.13MMr. Jacob Steven Leach (Age 46)Executive VP & COO Comp: $1.29MMr. Michael Jon Brown (Age 54)Executive VP & Chief Legal Officer Comp: $1.22MMs. Teri Lawver (Age 57)Executive VP & Chief Commercial Officer Comp: $1.41MMr. Girish Naganathan (Age 47)Executive VP & CTO Comp: $423.92kMr. Shelly Ramasamy Selvaraj (Age 65)Senior VP & Chief Information Officer Mr. Sean ChristensenDirector of Corporate Affairs & Head of Investor RelationsMr. Matthew Dolan (Age 43)Executive Vice President of Strategy, Corporate Development & Dexcom Labs Ms. Leverne MarshExecutive Vice President of MarketingMore ExecutivesKey CompetitorsAbiomedNASDAQ:ABMDNovoCureNASDAQ:NVCRBecton, Dickinson and CompanyNYSE:BDXEdwards LifesciencesNYSE:EWIDEXX LaboratoriesNASDAQ:IDXXView All CompetitorsInsiders & InstitutionsCim LLCBought 432 shares on 9/6/2024Ownership: 0.003%Sanctuary Advisors LLCBought 11,220 shares on 9/5/2024Ownership: 0.003%Brown Financial AdvisorsBought 10,902 shares on 8/30/2024Ownership: 0.003%Clearbridge Investments LLCSold 3,515 shares on 8/27/2024Ownership: 0.009%New Wave Wealth Advisors LLCBought 2,234 shares on 8/27/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions Should I Buy DexCom Stock? DXCM Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in DexCom, Inc.: DexCom, Inc. is a medical device company that focuses on continuous glucose monitoring (CGM) systems, a growing market due to the increasing prevalence of diabetes worldwide. Cons Investors should be bearish about investing in DexCom, Inc. for these reasons: Current stock price of DexCom, Inc. may be overvalued based on recent market trends and financial analysis. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 4, 2024. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com. DXCM Stock Analysis - Frequently Asked Questions How have DXCM shares performed this year? DexCom's stock was trading at $124.09 on January 1st, 2024. Since then, DXCM shares have decreased by 44.7% and is now trading at $68.61. View the best growth stocks for 2024 here. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) issued its earnings results on Thursday, July, 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. The firm's revenue for the quarter was up 15.3% compared to the same quarter last year. Read the conference call transcript. When did DexCom's stock split? DexCom's stock split before market open on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were payable to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. What is Kevin Sayer's approval rating as DexCom's CEO? 347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees. Does DexCom have any subsidiaries? DexCom subsidiaries include these companies: TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and others. Who are DexCom's major shareholders? DexCom's top institutional investors include Baillie Gifford & Co. (3.85%), Legal & General Group Plc (0.75%), Massachusetts Financial Services Co. MA (0.61%) and Vaughan Nelson Investment Management L.P. (0.41%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Steven Robert Pacelli, Jereme M Sylvain, Sadie Stern, Michael Jon Brown, Barry J Regan, Steven R Altman, Paul R Flynn, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Bridgette P Heller, Chad Patterson, Andrew K Balo, Barbara Kahn, Richard Alexander Collins, Mark G Foletta and Nicholas Augustinos. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM) and ServiceNow (NOW). This page (NASDAQ:DXCM) was last updated on 9/9/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredWall Street Insider Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DXCM Stock Alerts